The latest patent addresses reagent formulations for Orthopeutics’ injectable tissue-repair products. Orthopeutics has commenced the human clinical trials phase of NEXT for degenerative disc disease, engaging multiple clinical specialties to validate their custom injection-delivery protocol, with overseas first-in-man trials beginning soon.
More Articles on Orthopedic Devices:
Smith & Nephew Launches TRIGEN Low-Profile Screw
Mazor Robotics Finalizes $15M in Financing
Implantate Extends Contracts of All Board Members
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.